Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome.

Literature DB >> 29296808

Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome.

Yoko Yoshida¹, Masanori Matsumoto¹, Hideo Yagi¹, Ayami Isonishi¹, Kazuya Sakai¹, Masaki Hayakawa¹, Yuji Hori², Toshiyuki Sado³, Hiroshi Kobayashi³, Yoshihiro Fujimura².

Abstract

Severely decreased ADAMTS13 unbound to VWF may play a key role in the pathogenesis of HELLP syndrome.A qualitative ADAMTS13 assay may be important for diagnosing HELLP syndrome.

Entities: Disease Gene Species

Year: 2017 PMID： 29296808 PMCID： PMC5728335 DOI： 10.1182/bloodadvances.2017006767

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

12 in total

1. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium.

Authors: Analía Sánchez-Luceros; Susana S Meschengieser; Carlos Marchese; Roberto Votta; Patricia Casais; Adriana I Woods; María V Nadal; María J Salviú; María A Lazzari
Journal: Blood Coagul Fibrinolysis Date: 2003-10 Impact factor: 1.276

2. ADAMTS13 deficiency in severe postpartum HELLP syndrome.

Authors: Olivier Pourrat; Rémi Coudroy; Fabrice Pierre
Journal: Br J Haematol Date: 2013-07-24 Impact factor: 6.998

Review 3. Pathogenesis of preeclampsia.

Authors: Brett C Young; Richard J Levine; S Ananth Karumanchi
Journal: Annu Rev Pathol Date: 2010 Impact factor: 23.472

4. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?

Authors: Y Zhou; C H Damsky; S J Fisher
Journal: J Clin Invest Date: 1997-05-01 Impact factor: 14.808

5. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.

Authors: Seiji Kato; Masanori Matsumoto; Tomomi Matsuyama; Ayami Isonishi; Hisahide Hiura; Yoshihiro Fujimura
Journal: Transfusion Date: 2006-08 Impact factor: 3.157

6. Factor-VIII-related antigen: measurement by enzyme immunoassay.

Authors: A Bartlett; K M Dormandy; C M Hawkey; P Stableforth; A Voller
Journal: Br Med J Date: 1976-04-24

Review 7. Procoagulant and anticoagulant mechanisms in human placenta.

Authors: Naomi Lanir; Anat Aharon; Benjamin Brenner
Journal: Semin Thromb Hemost Date: 2003-04 Impact factor: 4.180

8. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma.

Authors: Ayami Isonishi; Charles L Bennett; Barbara Plaimauer; Friedrich Scheiflinger; Masanori Matsumoto; Yoshihiro Fujimura
Journal: Transfusion Date: 2015-06-08 Impact factor: 3.157

9. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.

Authors: Antonella Lattuada; Edoardo Rossi; Cinzia Calzarossa; Rosaria Candolfi; Pier Mannuccio Mannucci
Journal: Haematologica Date: 2003-09 Impact factor: 9.941

10. ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment.

Authors: Yuji Hori; Masaki Hayakawa; Ayami Isonishi; Kenji Soejima; Masanori Matsumoto; Yoshihiro Fujimura
Journal: Transfusion Date: 2013-04-08 Impact factor: 3.157

3 in total